Title |
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies
|
---|---|
Published in |
Risk Management and Healthcare Policy, October 2016
|
DOI | 10.2147/rmhp.s108586 |
Pubmed ID | |
Authors |
Kelly F Bell, Arie Katz, John J Sheehan |
Abstract |
The use of quality measures attempts to improve safety and health outcomes and to reduce costs. In two Phase III trials in treatment-naive patients with type 2 diabetes, dapagliflozin 5 or 10 mg/d as initial combination therapy with metformin extended-release (XR) significantly reduced glycated hemoglobin (A1C) from baseline to 24 weeks and allowed higher proportions of patients to achieve A1C <7% vs dapagliflozin or metformin monotherapy. A pooled analysis of data from these two studies assessed the effect of dapagliflozin 5 or 10 mg/d plus metformin XR (combination therapy) compared with placebo plus metformin XR (metformin monotherapy) on diabetes quality measures. Quality measures include laboratory measures of A1C and low-density lipoprotein cholesterol (LDL-C) as well as vital status measures of blood pressure (BP) and body mass index (BMI). The proportion of patients achieving A1C, BP, and LDL-C individual and composite measures was assessed, as was the proportion with baseline BMI ≥25 kg/m(2) who lost ≥4.5 kg. Subgroup analyses by baseline BMI were also performed. A total of 194 and 211 patients were treated with dapagliflozin 5- or 10-mg/d combination therapy, respectively, and 409 with metformin monotherapy. Significantly higher proportions of patients achieved A1C ≤6.5%, <7%, or <8% with combination therapy vs metformin monotherapy (P<0.02). Significantly higher proportions of patients achieved BP <140/90 mmHg (P<0.02 for each dapagliflozin dose) and BP <130/80 mmHg (P<0.02 with dapagliflozin 5 mg/d only) with combination therapy vs metformin monotherapy. Similar proportions (29%-33%) of patients had LDL-C <100 mg/dL across treatment groups. A higher proportion of patients with baseline BMI ≥25 kg/m(2) lost ≥4.5 kg with combination therapy. Combination therapy had a more robust effect on patients with higher baseline BMI. Initial combination therapy with dapagliflozin 5 or 10 mg/d and metformin improved quality measures relevant to clinical outcomes and diabetes care. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 16% |
Student > Ph. D. Student | 7 | 16% |
Other | 6 | 14% |
Researcher | 5 | 12% |
Student > Bachelor | 4 | 9% |
Other | 4 | 9% |
Unknown | 10 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 22 | 51% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Agricultural and Biological Sciences | 1 | 2% |
Nursing and Health Professions | 1 | 2% |
Other | 0 | 0% |
Unknown | 14 | 33% |